Verici Dx (OTCPK:VRCDF) Cash-to-Debt

: No Debt (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Verici Dx's cash to debt ratio for the quarter that ended in Jun. 2022 was No Debt.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Verici Dx could pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

The historical rank and industry rank for Verici Dx's Cash-to-Debt or its related term are showing as below:

VRCDF' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 2 years, Verici Dx's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

VRCDF's Cash-to-Debt is ranked better than
99.14% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.58 vs VRCDF: No Debt

Verici Dx Cash-to-Debt Historical Data

The historical data trend for Verici Dx's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Annual Data

Trend

Dec20

Dec21

Cash-to-Debt

239.88

No Debt

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22
Cash-to-Debt	No Debt	No Debt	No Debt

Competitive Comparison

For the Diagnostics & Research subindustry, Verici Dx's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Verici Dx Cash-to-Debt Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Verici Dx's Cash-to-Debt falls in comparison to its industry or sector. The grey bar indicates the Cash-to-Debt's extreme value range as defined by GuruFocus.

Verici Dx Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Verici Dx's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Verici Dx had no debt.

Verici Dx's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

Verici Dx had no debt.

Verici Dx (OTCPK:VRCDF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Verici Dx Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Verici Dx's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (OTCPK:VRCDF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialisation: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels.

Verici Dx (OTCPK:VRCDF) Headlines

No Headlines